Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 1.12
NAS:KERX's Cash-to-Debt is ranked lower than
85% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:KERX: 1.12 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:KERX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.73  Med: No Debt Max: No Debt
Current: 1.12
Equity-to-Asset 0.14
NAS:KERX's Equity-to-Asset is ranked lower than
94% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:KERX: 0.14 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:KERX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.18  Med: 0.79 Max: 0.93
Current: 0.14
-0.18
0.93
Debt-to-Equity 4.87
NAS:KERX's Debt-to-Equity is ranked lower than
99.99% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:KERX: 4.87 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:KERX' s Debt-to-Equity Range Over the Past 10 Years
Min: -15.07  Med: 2.09 Max: 5.69
Current: 4.87
-15.07
5.69
Piotroski F-Score: 2
Altman Z-Score: -5.47
Beneish M-Score: -31.84
WACC vs ROIC
23.68%
-871.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -286.45
NAS:KERX's Operating Margin % is ranked lower than
64% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:KERX: -286.45 )
Ranked among companies with meaningful Operating Margin % only.
NAS:KERX' s Operating Margin % Range Over the Past 10 Years
Min: -9016.3  Med: -742.26 Max: 38.97
Current: -286.45
-9016.3
38.97
Net Margin % -431.89
NAS:KERX's Net Margin % is ranked lower than
66% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:KERX: -431.89 )
Ranked among companies with meaningful Net Margin % only.
NAS:KERX' s Net Margin % Range Over the Past 10 Years
Min: -8585.51  Med: -783.89 Max: 41.62
Current: -431.89
-8585.51
41.62
ROE % -1206.41
NAS:KERX's ROE % is ranked lower than
98% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:KERX: -1206.41 )
Ranked among companies with meaningful ROE % only.
NAS:KERX' s ROE % Range Over the Past 10 Years
Min: -1206.41  Med: -131.46 Max: 68.51
Current: -1206.41
-1206.41
68.51
ROA % -110.95
NAS:KERX's ROA % is ranked lower than
80% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:KERX: -110.95 )
Ranked among companies with meaningful ROA % only.
NAS:KERX' s ROA % Range Over the Past 10 Years
Min: -135.67  Med: -77.46 Max: 31.09
Current: -110.95
-135.67
31.09
ROC (Joel Greenblatt) % -967.29
NAS:KERX's ROC (Joel Greenblatt) % is ranked lower than
61% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:KERX: -967.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:KERX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -46369.35  Med: -7580 Max: 7114.49
Current: -967.29
-46369.35
7114.49
3-Year Revenue Growth Rate 52.00
NAS:KERX's 3-Year Revenue Growth Rate is ranked higher than
87% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:KERX: 52.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:KERX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50 Max: 237.3
Current: 52
0
237.3
3-Year EBITDA Growth Rate 27.00
NAS:KERX's 3-Year EBITDA Growth Rate is ranked higher than
78% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:KERX: 27.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:KERX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -45.1  Med: 17.7 Max: 70.9
Current: 27
-45.1
70.9
3-Year EPS without NRI Growth Rate 37.90
NAS:KERX's 3-Year EPS without NRI Growth Rate is ranked higher than
86% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:KERX: 37.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:KERX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.7  Med: 18 Max: 60
Current: 37.9
-44.7
60
GuruFocus has detected 4 Warning Signs with Keryx Biopharmaceuticals Inc $NAS:KERX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:KERX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

KERX Guru Trades in Q3 2016

Seth Klarman 25,791,678 sh (unchged)
David Abrams 5,719,176 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Chuck Royce 317,725 sh (-29.66%)
» More
Q4 2016

KERX Guru Trades in Q4 2016

Joel Greenblatt 76,726 sh (New)
Seth Klarman 25,791,678 sh (unchged)
David Abrams 5,719,176 sh (unchged)
Chuck Royce 256,725 sh (-19.20%)
» More
Q1 2017

KERX Guru Trades in Q1 2017

Steven Cohen 100,000 sh (New)
Chuck Royce 256,725 sh (unchged)
David Abrams 5,719,176 sh (unchged)
Seth Klarman 25,791,678 sh (unchged)
Joel Greenblatt Sold Out
» More
Q2 2017

KERX Guru Trades in Q2 2017

Joel Greenblatt 55,639 sh (New)
Steven Cohen 1,552,700 sh (+1452.70%)
David Abrams 5,719,176 sh (unchged)
Seth Klarman 25,791,678 sh (unchged)
Chuck Royce 256,725 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:KERX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 New Buy0.01%$5.55 - $7.04 $ 6.9512%55,639
Joel Greenblatt 2017-03-31 Sold Out 0.01%$4.59 - $6.4 $ 6.9527%0
Joel Greenblatt 2016-12-31 New Buy0.01%$4.16 - $6.41 $ 6.9527%76,726
Joel Greenblatt 2016-09-30 Sold Out 0.01%$4.1 - $7.53 $ 6.9529%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ITCI, NAS:SPPI, NAS:ENTA, NAS:BYSI, NAS:EDIT, NAS:ADRO, NAS:RGNX, NAS:ZIOP, NAS:TGTX, NAS:VNDA, NAS:NTLA, NAS:ANIK, NAS:AKBA, NAS:RETA, NAS:PTCT, NAS:AMRI, NAS:IMGN, NAS:CYTK, NAS:RVNC, NAS:ARNA » details
Traded in other countries:KYX.Germany,
Headquarter Location:USA
Keryx Biopharmaceuticals Inc acquires and develops novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.

Keryx Biopharmaceuticals acquires and develops novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx commenced operations in 1999 and has three key products in clinical trials for kidney disease and various cancers. The company acquired a renal disease-related drug candidate, Zerenex, and an approved diagnostic product, Accumin, in 2006.

Top Ranked Articles about Keryx Biopharmaceuticals Inc

Keryx Biopharmaceuticals Announces Changes to its Board of Directors
Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in September 2017
Keryx Biopharmaceuticals to Webcast its Presentation at Canaccord Genuity’s 37th Annual Growth Conference on August 9, 2017
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2017 Financial Results on Thursday, July 27, 2017
Keryx Biopharmaceuticals to Webcast its Presentation at Jefferies’ 2017 Healthcare Conference on June 6, 2017
Keryx Biopharmaceuticals Announces First Quarter 2017 Financial Results
Keryx Announces that Auryxia® (Ferric Citrate) is Now on Formulary at All Major Medicare Part D Plans
Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2017 Financial Results on Thursday, May 4, 2017
Keryx Announces the Largest Medicare Part D Plan Sponsor Added Auryxia® to its Medicare Part D Plan Formularies

Additional formularies expand unrestricted access to Auryxia to approximately 85 percent of phosphate binder patients across Medicare Part D and commercial insurance providers

BOSTON, March 20, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced that the nation’s largest Medicare Part D plan sponsor has added Auryxia® (ferric citrate) to its Medicare Part D plan formularies, effective immediately. Auryxia is currently indicated in the U.S. for the control of serum phosphorus levels in people with chronic kidney disease (CKD) on dialysis. Addition to these Part D plan formularies significantly increases unrestricted access to Auryxia for people on dialysis and their caregivers.  “We are pleased that another large insurance provider has recognized the value that Auryxia can bring to patients,” said Greg Madison, president and chief executive officer of Keryx Biopharmaceuticals. “The addition to these formularies, which covers both the remainder of 2017 and the full year 2018, will support continuing growth of Auryxia in dialysis as well as ensuring that we can provide broad access to Auryxia for people with iron deficiency anemia (IDA) and non-dialysis dependent (NDD) CKD, pending approval of this indication later this year.” It is estimated that there are approximately 450,000 people in the U.S. who have End Stage Renal Disease (ESRD) and who require dialysis treatment. The majority of ESRD patients require chronic treatment with phosphate-binding medicines to lower and maintain serum phosphorus at acceptable levels. Medicare Part D and commercial insurance companies cover most of the prescription costs for people with ESRD, including the vast majority of phosphate binder prescriptions.   Keryx is seeking a label expansion for ferric citrate to include the treatment of iron deficiency anemia in adults with non-dialysis dependent CKD. A supplemental new drug application is under review by the U.S. FDA, with a Prescription Drug User Fee Act (PDUFA) target action date of November 6, 2017 for completion. About Auryxia® Auryxia (ferric citrate) was approved by the U.S. Food and Drug Administration on September 5, 2014 and is indicated in the U.S. for the control of serum phosphorus levels in patients with CKD on dialysis. The U.S. approval of Auryxia was based on data from the company's Phase 3 registration program in dialysis patients. In the Phase 3 clinical trials, Auryxia effectively reduced serum phosphorus levels to within the established guidelines range of 3.5 to 5.5 mg/dL. Auryxia binds with dietary phosphate in the GI tract and precipitates as ferric phosphate. The unbound portion of Auryxia has been shown to increase serum iron parameters including ferritin and transferrin saturation (TSAT). Iron absorption from Auryxia may lead to excessive elevations in iron stores. Accordingly, physicians should assess and monitor iron parameters before starting and while on Auryxia, and may need to decrease or discontinue IV iron for these patients. The most common adverse events for Auryxia treated patients were gastrointestinal related, including diarrhea, nausea, vomiting and constipation. For more information about Auryxia and the U.S. full prescribing information, visit www.Auryxia.com. Use of ferric citrate in patients with NDD-CKD and IDA, as highlighted above, is investigational and has not been determined to be safe or efficacious. IMPORTANT U.S. SAFETY INFORMATION FOR AURYXIA® (ferric citrate) Contraindication: Patients with iron overload syndrome, e.g. hemochromatosis, should not take Auryxia®. Iron Overload: Iron absorption from Auryxia may lead to increased iron in storage sites. Iron parameters should be monitored prior to and while on Auryxia. Patients receiving IV iron may require a reduction in dose or discontinuation of IV iron therapy. Accidental Overdose of Iron: Accidental overdose of iron containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep Auryxia away from children as it contains iron. Call a poison control center or your physician in case of an accidental overdose in a child. Patients with Gastrointestinal Bleeding or Inflammation: Safety has not been established for these patients. Adverse Events: The most common adverse events with Auryxia were diarrhea (21%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%). Gastrointestinal adverse reactions were the most common reason for discontinuing Auryxia (14%). Auryxia contains iron and may cause dark stools, which is considered normal with oral medications containing iron. Drug Interactions: Doxycycline should be taken at least 1 hour before Auryxia. Ciprofloxacin should be taken at least 2 hours before or after Auryxia. For Full Prescribing Information for Auryxia, please visit http://auryxia.com/important-safety-information/ Forward Looking Statements
Some of the statements included in this press release, particularly those regarding the commercialization and ongoing clinical development of Auryxia, the expected impact of the new formulary coverage for Auryxia and the submission of an sNDA to the FDA to expand the label of ferric citrate to include the treatment of IDA in adults with stage 3-5 NDD-CKD and the potential approval in this indication and the impact thereof on Keryx, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: whether we can increase adoption of Auryxia in patients with CKD on dialysis; the risk that expanded formulary access to Auryxia may not lead to increased adoption or sales; the risk that the FDA may not concur with our interpretation of our Phase 3 study results in NDD- CKD, supportive data, conduct of the studies, or any other part of our regulatory submission and could ultimately deny approval of ferric citrate for the treatment of IDA in adults with stage 3-5 NDD-CKD; the risk that if approved for use in NDD-CKD that we may not be able to successfully market Auryxia for use in this indication; our ability to continue to supply Auryxia following the recent resupply to the market; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only. About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is a commercial stage company focused on bringing innovative medicines to people with renal disease. Keryx developed and commercializes Auryxia® (ferric citrate), an iron-based phosphate binder, in the U.S. Ferric citrate is marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). Keryx has programs underway to leverage its development and commercial infrastructure, including evaluation of iron deficiency anemia in adults with non-dialysis depended chronic kidney disease and in-licensing medicines for renal disease. For more information about Keryx, please visit www.keryx.com.
KERYX BIOPHARMACEUTICALS CONTACTS:
Amy Sullivan
Senior Vice President, Corporate Affairs
T: 617.466.3519
[email protected]

Lora Pike
Senior Director, Investor Relations
T: 617.466.3511
[email protected]

Read more...
Keryx Biopharmaceuticals Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Auryxia® (ferric citrate) Tablets

BOSTON, March 08, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Auryxia® (ferric citrate) tablets. The sNDA acceptance by the FDA indicates that the application is sufficiently complete to permit a substantive review. The Prescription Drug User Fee Act (PDUFA) target action date for completion of the FDA’s review is November 6, 2017.
Auryxia is currently approved for use in the U.S. for the control of serum phosphorus levels in patients with end-stage renal disease requiring dialysis. Keryx, with this sNDA submission, is seeking to expand the indication for Auryxia to include the treatment of iron deficiency anemia (IDA) in patients with non-dialysis dependent chronic kidney disease (NDD-CKD). “Iron deficiency anemia is a common complication in people with non-dialysis dependent chronic kidney disease, yet currently there are no FDA-approved oral medicines to treat this debilitating disease,” said John Neylan, M.D., senior vice president and chief medical officer of Keryx Biopharmaceuticals. “Acceptance of the sNDA filing not only brings us one step closer to providing this medicine to patients in need; it is an important milestone for the company and our efforts to leverage ferric citrate’s mechanism of action.”   The sNDA was based on data from a 24-week placebo controlled Phase 3 trial in 234 adults with stage 3-5 NDD-CKD. Patients enrolled in the trial had hemoglobin levels between 9.0 g/dL and 11.5 g/dL and were intolerant to or had an inadequate response to prior treatment with oral iron supplements. The starting dose in the study was three tablets per day taken with meals. Importantly, during the study, patients were not allowed to receive any IV or oral iron, or ESAs. In the study, treatment with Auryxia demonstrated significant increases in hemoglobin levels of >1 g/dL at any point during the 16-week efficacy period for the majority of patients (52.1 percent; n=61/117), a clinically meaningful result. In the trial, ferric citrate was generally well tolerated and adverse events were consistent with its known safety profile, with diarrhea reported as the most common adverse event. About Iron Deficiency Anemia, NDD-CKD
Keryx estimates that of the 1.7 million Americans with NDD-CKD under the care of a nephrologist, approximately 650,000 are treated for IDA and another 250,000 – 400,000 could have IDA but are not treated today. The prevalence and severity of IDA increases as kidney disease progresses. According to market research, nephrologists report that the majority of their patients are sub-optimally treated with currently available oral iron supplements and that a need exists for a new treatment option for their patients with iron deficiency anemia and NDD-CKD. About Auryxia
Auryxia (ferric citrate) was approved by the U.S. Food and Drug Administration on September 5, 2014 and is indicated in the U.S. for the control of serum phosphorus levels in patients with CKD on dialysis. Each Auryxia tablet contains 210 mg of ferric iron, equivalent to 1 g of ferric citrate. The U.S. approval of Auryxia was based on data from the company's Phase 3 registration program in dialysis patients. In the Phase 3 clinical trials, Auryxia effectively reduced serum phosphorus levels to within the KDOQI guidelines range of 3.5 to 5.5 mg/dL. Auryxia binds with dietary phosphate in the GI tract and precipitates as ferric phosphate. The unbound portion of Auryxia has been shown to increase serum iron parameters including ferritin and transferrin saturation (TSAT). Iron absorption from Auryxia may lead to excessive elevations in iron stores. Accordingly, physicians should assess and monitor iron parameters before starting and while on Auryxia, and may need to decrease or discontinue IV iron for these patients. The most common adverse events for Auryxia treated patients were gastrointestinal related, including diarrhea, nausea, vomiting and constipation. For more information about Auryxia and the U.S. full prescribing information, visit www.Auryxia.com. Use of ferric citrate in patients with NDD-CKD and IDA, as highlighted above, is investigational and has not been determined to be safe or efficacious. IMPORTANT U.S. SAFETY INFORMATION FOR AURYXIA® (ferric citrate) Contraindication: Patients with iron overload syndrome, e.g. hemochromatosis, should not take Auryxia®. Iron Overload: Iron absorption from Auryxia may lead to increased iron in storage sites. Iron parameters should be monitored prior to and while on Auryxia. Patients receiving IV iron may require a reduction in dose or discontinuation of IV iron therapy. Accidental Overdose of Iron: Accidental overdose of iron containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep Auryxia away from children as it contains iron. Call a poison control center or your physician in case of an accidental overdose in a child. Patients with Gastrointestinal Bleeding or Inflammation: Safety has not been established for these patients. Adverse Events: The most common adverse events with Auryxia were diarrhea (21%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%). Gastrointestinal adverse reactions were the most common reason for discontinuing Auryxia (14%). Auryxia contains iron and may cause dark stools, which is considered normal with oral medications containing iron. Drug Interactions: Doxycycline should be taken at least 1 hour before Auryxia. Ciprofloxacin should be taken at least 2 hours before or after Auryxia. For Full Prescribing Information for Auryxia, please visit http://auryxia.com/important-safety-information/ Forward Looking Statements
Some of the statements included in this press release, particularly those regarding the commercialization and ongoing clinical development of Auryxia and the FDA’s acceptance of the sNDA to expand the label of ferric citrate to include the treatment of IDA in adults with stage 3-5 NDD-CKD and the potential approval in this indication and the impact thereof on Keryx, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: whether we can increase adoption of Auryxia in patients with CKD on dialysis; the risk that the FDA may not concur with our interpretation of our Phase 3 study results in NDD-CKD, supportive data, conduct of the studies, or any other part of our regulatory submission and could ultimately deny approval of ferric citrate for the treatment of IDA in adults with stage 3-5 NDD-CKD; the risk that if approved for use in NDD-CKD that we may not be able to successfully market Auryxia for use in this indication; our ability to continue to supply Auryxia following the recent resupply to the market; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only. About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is a commercial stage company focused on bringing innovative medicines to people with renal disease. Keryx developed and commercializes Auryxia® (ferric citrate), an iron-based phosphate binder, in the U.S. Ferric citrate is marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). Keryx has programs underway to leverage its development and commercial infrastructure, including evaluation of iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease and in-licensing medicines for renal disease. For more information about Keryx, please visit www.keryx.com.
KERYX BIOPHARMACEUTICALS CONTACTS:
Amy Sullivan
Senior Vice President, Corporate Affairs
T: 617.466.3519
[email protected]

Lora Pike
Senior Director, Investor Relations
T: 617.466.3511
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 32.15
KERX's PB Ratio is ranked lower than
99.99% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. KERX: 32.15 )
Ranked among companies with meaningful PB Ratio only.
KERX' s PB Ratio Range Over the Past 10 Years
Min: 1.85  Med: 7.71 Max: 68.57
Current: 32.15
1.85
68.57
PS Ratio 17.56
KERX's PS Ratio is ranked lower than
62% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. KERX: 17.56 )
Ranked among companies with meaningful PS Ratio only.
KERX' s PS Ratio Range Over the Past 10 Years
Min: 1.18  Med: 51.33 Max: 2228
Current: 17.56
1.18
2228
EV-to-EBIT -6.34
KERX's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. KERX: -6.34 )
Ranked among companies with meaningful EV-to-EBIT only.
KERX' s EV-to-EBIT Range Over the Past 10 Years
Min: -29.7  Med: -5.35 Max: 54.6
Current: -6.34
-29.7
54.6
EV-to-EBITDA -6.42
KERX's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. KERX: -6.42 )
Ranked among companies with meaningful EV-to-EBITDA only.
KERX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -29.7  Med: -5.4 Max: 53.7
Current: -6.42
-29.7
53.7
EV-to-Revenue 18.84
KERX's EV-to-Revenue is ranked lower than
63% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. KERX: 18.84 )
Ranked among companies with meaningful EV-to-Revenue only.
KERX' s EV-to-Revenue Range Over the Past 10 Years
Min: -7.3  Med: 44 Max: 1705.9
Current: 18.84
-7.3
1705.9
Current Ratio 5.76
KERX's Current Ratio is ranked higher than
60% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. KERX: 5.76 )
Ranked among companies with meaningful Current Ratio only.
KERX' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 6.99 Max: 106.93
Current: 5.76
1.88
106.93
Quick Ratio 5.16
KERX's Quick Ratio is ranked higher than
57% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. KERX: 5.16 )
Ranked among companies with meaningful Quick Ratio only.
KERX' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 6.94 Max: 106.93
Current: 5.16
1.88
106.93
Days Inventory 181.19
KERX's Days Inventory is ranked lower than
75% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. KERX: 181.19 )
Ranked among companies with meaningful Days Inventory only.
KERX' s Days Inventory Range Over the Past 10 Years
Min: 181.19  Med: 1365.48 Max: 2886.82
Current: 181.19
181.19
2886.82
Days Sales Outstanding 72.08
KERX's Days Sales Outstanding is ranked higher than
54% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. KERX: 72.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
KERX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.51  Med: 28.12 Max: 98.47
Current: 72.08
0.51
98.47
Days Payable 64.95
KERX's Days Payable is ranked lower than
79% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. KERX: 64.95 )
Ranked among companies with meaningful Days Payable only.
KERX' s Days Payable Range Over the Past 10 Years
Min: 19.96  Med: 463.34 Max: 42743.3
Current: 64.95
19.96
42743.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.60
KERX's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. KERX: -8.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KERX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -34.8  Med: -11.9 Max: -6.3
Current: -8.6
-34.8
-6.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 49.64
KERX's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. KERX: 49.64 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
KERX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.07  Med: 7.45 Max: 53.43
Current: 49.64
1.07
53.43
Price-to-Tangible-Book 36.58
KERX's Price-to-Tangible-Book is ranked lower than
99.99% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. KERX: 36.58 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
KERX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.93  Med: 6.45 Max: 39.37
Current: 36.58
0.93
39.37
Price-to-Median-PS-Value 0.34
KERX's Price-to-Median-PS-Value is ranked higher than
84% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. KERX: 0.34 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
KERX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.03  Med: 1.89 Max: 95.5
Current: 0.34
0.03
95.5
Earnings Yield (Greenblatt) % -15.59
KERX's Earnings Yield (Greenblatt) % is ranked lower than
65% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. KERX: -15.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KERX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -77911.5  Med: -11.6 Max: 27616.5
Current: -15.59
-77911.5
27616.5

More Statistics

Revenue (TTM) (Mil) $42.83
EPS (TTM) $ -1.69
Beta3.41
Short Percentage of Float22.27%
52-Week Range $4.11 - 8.38
Shares Outstanding (Mil)118.75

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 66 106 148 194
EPS ($) -0.56 -0.30 0.08 0.37
EPS without NRI ($) -0.56 -0.30 0.08 0.37
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:KERX

Headlines

Articles On GuruFocus.com
Keryx Biopharmaceuticals Announces Changes to its Board of Directors Sep 13 2017 
Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in Septembe Sep 05 2017 
Keryx Biopharmaceuticals to Webcast its Presentation at Canaccord Genuity’s 37th Annual Growth Aug 04 2017 
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2017 Financial Results on Thursda Jul 19 2017 
Keryx Biopharmaceuticals to Webcast its Presentation at Jefferies’ 2017 Healthcare Conference o May 30 2017 
Keryx Biopharmaceuticals Announces First Quarter 2017 Financial Results May 04 2017 
Keryx Announces that Auryxia® (Ferric Citrate) is Now on Formulary at All Major Medicare Part D P May 01 2017 
Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2017 Financial Results on Thursday Apr 18 2017 
Keryx Announces the Largest Medicare Part D Plan Sponsor Added Auryxia® to its Medicare Part D Pl Mar 20 2017 
Keryx Biopharmaceuticals Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application f Mar 08 2017 

More From Other Websites
Here's Why These 3 Biotech Stocks Might Stop Rallying Sep 20 2017
Keryx Biopharmaceuticals, Inc. (KERX) Catches Eye: Stock Jumps 5.9% Sep 18 2017
Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US :... Sep 15 2017
Keryx Biopharmaceuticals Announces Changes to its Board of Directors Sep 13 2017
Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in... Sep 05 2017
Keryx Biopharmaceuticals, Inc. – Value Analysis (NASDAQ:KERX) : September 2, 2017 Sep 01 2017
Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : KERX-US :... Aug 29 2017
Edited Transcript of KERX earnings conference call or presentation 27-Jul-17 12:00pm GMT Aug 13 2017
ETFs with exposure to Keryx Biopharmaceuticals, Inc. : August 11, 2017 Aug 11 2017
Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US :... Aug 07 2017
Keryx Biopharmaceuticals to Webcast its Presentation at Canaccord Genuity’s 37th Annual Growth... Aug 04 2017
3 Biotech Stocks With Big News Coming Aug 02 2017
Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017 Jul 28 2017
Keryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat Jul 28 2017
Keryx Biopharma reports 2Q loss Jul 27 2017
ETFs with exposure to Keryx Biopharmaceuticals, Inc. : July 27, 2017 Jul 27 2017
Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S.... Jul 27 2017
3 Beaten-Up Biotechs Bouncing Back in 2017 (Hint: One Is a Marijuana Stock) Jul 23 2017
What to Expect from Keryx (KERX) this Earnings Season? Jul 21 2017
Biotech Bulletin of the Week: Gilead Sciences, Inc. (GILD), Vertex Pharmaceuticals Incorporated... Jul 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}